Two decades since the development of effective antiretroviral therapy (ART) for HIV infection, HIV-positive people who use illicit drugs (PWUD) continue to experience persistent disparities in HIV treatment outcomes. Although the deleterious impact of high-intensity illicit drug use on access and adherence to ART is clear, the social, structural and economic barriers to engagement and retention in HIV care remain incompletely described, and there is an urgent need to identify aspects of treatment for HIV and addiction that promote optimal HIV treatment outcomes. At the same time, there is an increasing appreciation of the importance of HIV-associated comorbidities, coinfections and complications?especially immunologic dysfunction, chronic inflammation and premature aging?on HIV disease outcomes, even among HIV-positive individuals optimally engaged in ART. Although the impact of some comorbidities, such as hepatitis C virus co-infection, on HIV-positive PWUD are well described, we are unaware of any longitudinal study using a validated measure incorporating HIV- and non- HIV-related clinical biomarkers to systematically investigate HIV disease severity, and the impact of illicit drug use and related social, structural and economic factors, among HIV-positive PWUD in a setting of no-cost universal medical care including all ART and medications for addiction treatment. Thus, in this application, we propose novel and significant investigations into the individual, social, structural and economic determinants of HIV treatment and disease outcomes among PWUD. Specifically, through the renewal of funding for a longstanding community-recruited prospective cohort of more than 1000 HIV-positive PWUD linked to comprehensive clinical monitoring data in Vancouver, Canada, we propose to: analyze the implementation, uptake and impact of new and emerging treatment for HIV and addiction on the achievement and maintenance of optimal HIV treatment and disease outcomes; investigate the impacts of established and emerging illicit drug use patterns and evolving approaches to addiction treatment on HIV treatment and disease outcomes; explore the interrelationships between social, structural and economic forces and illicit drug use patterns on HIV disease outcomes; and continue to serve as a NIDA-funded cohort that is a platform for a range of epidemiological, phylogenetic/bioinformatic and basic research into HIV acquisition, transmission and pathogenesis among people who use illicit drugs. This proposal to renew our research program exploits several established and emerging facets of the local environment, including: a centralized program of universal access to no-cost medical care, allowing for the complete ascertainment of clinical data free of the confounding influence of financial ability; the ongoing development of a range of innovative HIV and addiction programs for PWUD, including initiation of ART upon HIV diagnosis, harm-reduction-based HIV prevention and treatment supports; and novel approaches to manage opioid and stimulant use disorders. Our proposal is well aligned with recent calls for high-priority research to reduce disparities in HIV treatment and disease outcomes among HIV-positive PWUD through evidence to promote engagement and retention in HIV care and reduce the effect of comorbidities, complications and coinfections.

Public Health Relevance

The purpose of this proposed cohort study is to investigate HIV-related disparities, evaluate the uptake and impact of the next generation of HIV treatment, and study the effects of coinfections, comorbidities and complications on HIV disease outcomes. This study will involve 1000 HIV-positive people who use illicit drugs in Vancouver, Canada.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DA021525-14
Application #
9897499
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Schulden, Jeffrey D
Project Start
2007-09-17
Project End
2022-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
14
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of British Columbia
Department
Type
DUNS #
251949962
City
Vancouver
State
BC
Country
Canada
Zip Code
V6 1Z3
Mohd Salleh, Nur Afiqah; Richardson, Lindsey; Kerr, Thomas et al. (2018) A Longitudinal Analysis of Daily Pill Burden and Likelihood of Optimal Adherence to Antiretroviral Therapy Among People Living With HIV Who Use Drugs. J Addict Med 12:308-314
Ho, Joel; DeBeck, Kora; Milloy, M-J et al. (2018) Increasing availability of illicit and prescription opioids among people who inject drugs in a Canadian setting, 2010-2014. Am J Drug Alcohol Abuse 44:368-377
Klimas, Jan; Nosova, Ekaterina; Socías, Eugenia et al. (2018) Factors associated with discontinuation of methadone maintenance therapy (MMT) among persons who use alcohol in Vancouver, Canada. Drug Alcohol Depend 186:182-186
Socías, M Eugenia; Wood, Evan; Kerr, Thomas et al. (2018) Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016. Drug Alcohol Depend 189:90-95
Boyd, Jade; Richardson, Lindsey; Anderson, Solanna et al. (2018) Transitions in income generation among marginalized people who use drugs: A qualitative study on recycling and vulnerability to violence. Int J Drug Policy 59:36-43
Reddon, Hudson; Pettes, Tyler; Wood, Evan et al. (2018) Incidence and predictors of mental health disorder diagnoses among people who inject drugs in a Canadian setting. Drug Alcohol Rev 37 Suppl 1:S285-S293
Walton, Geoffrey; Dong, Huiru; Milloy, M J et al. (2018) Increasing availability of benzodiazepines among people who inject drugs in a Canadian setting. Subst Abus 39:69-76
Klimas, Jan; Dong, Huiru; Fairbairn, Nadia et al. (2018) Eligibility for heroin-assisted treatment (HAT) among people who inject opioids and are living with HIV in a Canadian setting. Addict Sci Clin Pract 13:3
Hayashi, Kanna; Milloy, M-J; Lysyshyn, Mark et al. (2018) Substance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: A cross-sectional urine toxicology screening study. Drug Alcohol Depend 183:1-6
Socías, Maria Eugenia; Wood, Evan; Lake, Stephanie et al. (2018) High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Addiction 113:2250-2258

Showing the most recent 10 out of 51 publications